What are the Historical Developments and Current Growth Metrics of the Coagulation Factor Deficiency Market?
The coagulation factor deficiency market has seen considerable growth due to a variety of factors.
• The market size for coagulation factor deficiency has exhibited robust growth over recent years. The market, which is expected to rise from $4.58 billion in 2024 to $4.94 billion in 2025, projects a compound annual growth rate (CAGR) of 8.0%.
Contributory factors to the remarkable growth rate during the historical period include the escalating prevalence of hemophilia, the advent of recombinant factors, the expanding awareness regarding coagulation disorders, and improvements in diagnostic abilities. Additional factors such as government aid for rare diseases, the advent of prophylactic treatments, the enlargement of patient registries, and the increase in biotechnology investments have also played a role.
What Does Future Hold for The Coagulation Factor Deficiency Market?
The coagulation factor deficiency market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations indicate a strong surge in the coagulation factor deficiency market in the upcoming years, with the market expected to culminate at a value of $6.64 billion in 2029, growing at a compounded annual growth rate (CAGR) of 7.7%.
The forecast period is expected to witness growth due to factors such as increased implementation of gene therapies, a heightened focus on personalized medications, a rise in coagulation disorders, growth in accessibility in burgeoning markets, and the integration of digital health solutions coupled with continuous innovation in biomanufacturing technologies. Noteworthy trends for the forecast period encompass gene editing techniques like CRISPR, the creation of long-acting recombinant factors, improvements in gene therapy delivery systems, wearable technology for coagulation monitoring, the use of artificial intelligence for treatment enhancements, point-of-care diagnostic instruments, nanoparticle-managed drug delivery, the development of plasma-free recombinant products, innovative biosimilar technologies, and the integration of precision medicine protocols.
What Factors Are Driving Growth In The Coagulation Factor Deficiency Market?
The escalation in cases of disorders associated with blood is expected to fuel the expansion of the coagulation factor deficiency market in the future. Disorders related to blood encompass a variety of conditions that influence the production, functioning, or composition of blood cells, platelets, or plasma, resulting in complications including anemia, clotting issues, or immune system deficiencies. The prevalence of these disorders is expected to rise due to elements such as an aging population, genetic susceptibility, increased awareness, environmental factors, lifestyle alterations, as well as a mounting burden of chronic illnesses and advancements in diagnostic technologies allowing for earlier detection. The coagulation factor deficiency assists in managing these disorders by supplying the necessary clotting elements to impede or regulate excessive bleeding, such as in conditions like hemophilia, where the body's intrinsic ability to form blood clots is deficient. For instance, in September 2024, according to the Leukemia and Lymphoma Society, a professional organization in the US, every 3 minutes an individual in the US is diagnosed with leukemia, lymphoma, or myeloma. In 2024, an estimated 187,740 individuals are affected by these cancers, accounting for 9.4% of the anticipated 2,001,140 new cancer incidences in the US. Additionally, in May 2024, according to the National Health Service (NHS) England, a state-funded healthcare system in the UK, around 17,000 people in England live with sickle cell disease, a hereditary blood disorder, with approximately 250 new cases being identified annually. Consequently, the surge in cases of blood-related disorders is propelling the growth of the coagulation factor deficiency market.
What Is The Segmentation Of The Global Coagulation Factor Deficiency Market?
The coagulation factor deficiency market covered in this report is segmented –
1) By Product: Recombinant Coagulation Factor Concentrates, Plasma-derived Coagulation Factor Concentrates, Biologics, Desmopressin, Other Product Types
2) By Deficiency Type: Haemophilia A, Hemophilia B, Von Willebrand Disease, Factor XI Deficiency, Factor XIII Deficiency, Other Treatment Types
3) By End Users: Hospitals, Clinics, Home Care, Other End Users
Subsegments:
1) By Recombinant Coagulation Factor Concentrates: Recombinant Factor VIII, Recombinant Factor IX, Recombinant Factor VIIa, Other Recombinant Factors
2) By Plasma-derived Coagulation Factor Concentrates: Plasma-derived Factor VIII, Plasma-derived Factor IX, Plasma-derived Factor VII, Other Plasma-derived Factors
3) By Biologics: Monoclonal Antibodies, Gene Therapy Products
4) By Desmopressin: Intravenous Desmopressin, Intranasal Desmopressin
5) By Other Product Types: Fresh Frozen Plasma (FFP), Prothrombin Complex Concentrates (PCC)
Pre-Book The Coagulation Factor Deficiency Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Shaping The Coagulation Factor Deficiency Market Landscape?
Prominent firms in the coagulation factor deficiency market are prioritizing the creation of novel treatments such as one-time gene therapy. This is meant to offer durable or possibly curative solutions to people suffering from bleeding conditions like hemophilia, thus diminishing the requirement for continuous transfusions of clotting elements. One-time gene therapy is a clinical procedure that entails the insertion or modification of genetic constituents within a patient's cells for disease treatment or cure. It aims to deliver extended or permanent therapeutic outcomes following a single application. For instance, Pfizer Inc., a US-based pharmaceutical and biotech enterprise, disclosed in April 2024 that the U.S. Food and Drug Administration (FDA) has sanctioned BEQVEZ (fidanacogene elaparvovec-dzkt) for therapeutic use in adults suffering from moderate to severe hemophilia B who are presently on factor IX (FIX) prophylaxis treatment. It is a one-off adeno-associated virus (AAV)-based gene therapy purposed to implant a working copy of the FIX gene, which encrypts a high-activity FIX variant, in the transduced cells. This gene therapy allows hemophilia B patients to generate FIX on their own through this solitary treatment, thereby eliminating the need for regular FIX transfusions.
Who Are the Key Players In The Coagulation Factor Deficiency Market?
Major companies operating in the coagulation factor deficiency market are:
• Pfizer Inc.
• F Hoffmann-La Roche Ltd.
• Bayer HealthCare Pharmaceuticals
• Sanofi Genzyme
• Novo Nordisk A/S
• Baxter International Inc.
• CSL Behring LLC
• Grifols S.A.
• Octapharma AG
• Takeda Pharmaceutical Company Limited
• Swedish Orphan Biovitrum AB
• GC Biopharma Co. Ltd.
• Alnylam Pharmaceuticals Inc.
• Opko Health Inc.
• Kedrion Biopharma Inc.
• Shanghai RAAS Blood Products Co. Ltd.
• LFB S.A.
• Biotest AG
• Spark Therapeutics Inc.
• Biogen Inc.
• Sangamo Therapeutics Inc.
• Centessa Pharmaceuticals Inc.
What Are The Regional Insights Into The Coagulation Factor Deficiency Market?
North America was the largest region in the coagulation factor deficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the coagulation factor deficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
